Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was bought at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the acquisition, the director now directly owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Standard BioTools Stock Performance
LAB stock opened at $1.06 on Wednesday. Standard BioTools Inc. has a 52 week low of $0.99 and a 52 week high of $3.04. The firm's fifty day moving average is $1.58 and its 200 day moving average is $1.79. The firm has a market cap of $394.59 million, a P/E ratio of -1.49 and a beta of 1.57.
Hedge Funds Weigh In On Standard BioTools
Several institutional investors and hedge funds have recently made changes to their positions in LAB. Hollow Brook Wealth Management LLC bought a new position in shares of Standard BioTools during the 3rd quarter valued at $10,679,000. Mirabella Financial Services LLP bought a new position in shares of Standard BioTools during the 4th quarter valued at $5,478,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Standard BioTools by 188.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company's stock valued at $4,719,000 after purchasing an additional 1,597,728 shares during the last quarter. State Street Corp grew its holdings in shares of Standard BioTools by 26.7% during the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company's stock valued at $10,606,000 after purchasing an additional 1,157,984 shares during the last quarter. Finally, Royce & Associates LP grew its holdings in shares of Standard BioTools by 136.8% during the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company's stock valued at $2,547,000 after purchasing an additional 840,951 shares during the last quarter. Institutional investors own 53.74% of the company's stock.
Analyst Ratings Changes
Separately, KeyCorp lowered shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.
Check Out Our Latest Report on LAB
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
